Pharmaceuticals News and Research

RSS

Pending cases against India's patent laws threaten public health, misinterpret international IP agreements, report says

"Pending cases against India's patent laws threaten public health and misinterpret international intellectual property (IP) agreements," researchers from Queen Mary, University of London argue in a special report published online in the Lancet on Monday, PharmaTimes reports.

13 Sep 2012

RPS honors Aston University professor with Pharmaceutical Scientist of the Year Award

Professor Yvonne Perrie, Chair in Drug Delivery at Aston University, Birmingham UK has won the prestigious Royal Pharmaceutical Society's Pharmaceutical Scientist of the Year Award for her contribution to developing a new tuberculosis vaccine.

13 Sep 2012

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

13 Sep 2012

Zhejiang Hisun Pharmaceuticals, Pfizer launch new joint venture

Pfizer Inc., the world's largest research-based pharmaceutical company, and Zhejiang Hisun Pharmaceuticals, a leading Chinese pharmaceutical company, today announced the launch of Hisun-Pfizer Pharmaceuticals Co., Ltd., a joint venture formed between the two companies to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets.

13 Sep 2012

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.

12 Sep 2012

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that MD Anderson Cancer Center in Houston, Texas has joined the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML).

12 Sep 2012

Aethic, King's College London to develop first sunscreen based on mycosporine-like amino acids

King's College London has entered into an agreement with skincare company Aethic to develop the first sunscreen based on MAA's (mycosporine-like amino acids), produced by coral.

12 Sep 2012

MHRA approves Sucampo’s AMITIZA to treat chronic idiopathic constipation in the U.K.

Sucampo Pharmaceuticals, Inc. today announced that it has received approval from the Medicines and Healthcare products Regulatory Agency for AMITIZA (lubiprostone) 24 mcg twice daily for the treatment of chronic idiopathic constipation (CIC) and associated symptoms in adults, when response to diet and other non-pharmacological measures (e.g., educational measures, physical activity) are inappropriate.

12 Sep 2012

Ethypharm, Ampio enter definitive agreement to manufacture Zertane

Ampio Pharmaceuticals, Inc. (AMPE), a clinical stage biopharmaceutical company, with repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction announced today that it has entered into a definitive agreement with Ethypharm Ltd for the manufacturing of Zertane, Ampio's drug for the treatment of premature ejaculation.

12 Sep 2012

Bruker launches BioPharmaCompass 1.1 software

At the 2012 CASSS 9th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry, Bruker today launches the first software solution to encompass the complete biopharmaceutical characterization challenge, including glycoforms, impurities and modifications.

From Bruker BioSpin Division 12 Sep 2012

Edison receives EMA COMP orphan designation for EPI-743 to treat Leigh syndrome

Edison Pharmaceuticals announced today that the Committee for Orphan Medicinal Products (COMP), European Medicines Agency, has granted orphan designation to EPI-743 for the treatment of Leigh syndrome.

12 Sep 2012

KaloBios commences KB003 Phase 2 trial in severe asthma

KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered monoclonal antibody, in subjects with severe asthma uncontrolled by corticosteroids.

12 Sep 2012

Pfizer, Visterra collaborate to discover novel antibodies

Visterra Inc., developer of novel therapeutics to treat major diseases, announced today that it has entered into a collaboration agreement with Pfizer to discover novel antibodies using Visterra's proprietary platform.

11 Sep 2012

GE Healthcare announces data from [18F]flutemetamol phase III studies on Alzheimer's

GE Healthcare today announced pooled results from phase III brain autopsy and biopsy studies on the investigational PET amyloid imaging agent, [18F]flutemetamol, which showed a strong concordance between [18F]flutemetamol images and Alzheimer's disease-associated beta amyloid brain pathology.

11 Sep 2012

Durata Therapeutics completes dalbavancin Phase 3 trials on ABSSSI

Durata Therapeutics today announced results from its QT study of the company's lead product candidate, dalbavancin. Dalbavancin is currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

11 Sep 2012

Palatin fourth quarter revenues decrease to $11,000

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2012.

11 Sep 2012

DATATRAK announces technology and services agreement with Bellicum

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the award of a multi-million dollar, five-year technology and services agreement with Bellicum Pharmaceuticals.

11 Sep 2012

U of I microbial engineer synthesizes 2-fucosyllactose to protect babies from pathogens

A University of Illinois microbial engineer has synthesized a sugar in human milk that is thought to protect babies from pathogens. That's important because 2FL, the shorthand scientists use to describe this human milk oligosaccharide (HMO), has not been added to infant formula because HMOs are incredibly expensive.

11 Sep 2012

Progestogens may avoid early child birth in women with prior preterm births

Pregnant women who have had prior preterm births may avoid a subsequent early birth if given progestogens, which are natural or synthetic forms of progesterone, a female hormone that naturally increases during pregnancy, a Vanderbilt analysis shows.

11 Sep 2012

Jazz Pharmaceuticals receives new U.S. patent for Xyrem oral solution

Jazz Pharmaceuticals plc. today announced that a new patent related to Xyrem (sodium oxybate) oral solution titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy" will issue today.

11 Sep 2012

Pharmaceuticals News and Research

Pending cases against India's patent laws threaten public health, misinterpret international IP agreements, report says

RPS honors Aston University professor with Pharmaceutical Scientist of the Year Award

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Zhejiang Hisun Pharmaceuticals, Pfizer launch new joint venture

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Aethic, King's College London to develop first sunscreen based on mycosporine-like amino acids

MHRA approves Sucampo’s AMITIZA to treat chronic idiopathic constipation in the U.K.

Ethypharm, Ampio enter definitive agreement to manufacture Zertane

Bruker launches BioPharmaCompass 1.1 software

Edison receives EMA COMP orphan designation for EPI-743 to treat Leigh syndrome

KaloBios commences KB003 Phase 2 trial in severe asthma

Pfizer, Visterra collaborate to discover novel antibodies

GE Healthcare announces data from [18F]flutemetamol phase III studies on Alzheimer's

Durata Therapeutics completes dalbavancin Phase 3 trials on ABSSSI

Palatin fourth quarter revenues decrease to $11,000

DATATRAK announces technology and services agreement with Bellicum

U of I microbial engineer synthesizes 2-fucosyllactose to protect babies from pathogens

Progestogens may avoid early child birth in women with prior preterm births

Jazz Pharmaceuticals receives new U.S. patent for Xyrem oral solution

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence